The good news is the final conditions for its takeover of German lupin protein manufacturer Prolupin have been met. It has been promised $6.2 million in a private placement at 20c a share, mainly from its largest shareholder, Fanja Pon, and its directors, and it is paying only $4.2m to buy Prolupin.
